Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 29 10:41AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.99 Insider Own3.48% Shs Outstand22.63M Perf Week-9.81%
Market Cap9.80M Forward P/E- EPS next Y-2.35 Insider Trans0.00% Shs Float21.84M Perf Month-5.27%
Income-35.03M PEG- EPS next Q-0.23 Inst Own13.11% Short Float1.38% Perf Quarter-38.16%
Sales12.00M P/S0.82 EPS this Y36.62% Inst Trans-15.90% Short Ratio0.24 Perf Half Y-41.10%
Book/sh-0.81 P/B- EPS next Y-37.83% ROA-86.16% Short Interest0.30M Perf Year-88.93%
Cash/sh0.81 P/C0.53 EPS next 5Y- ROE-426.64% 52W Range0.39 - 4.26 Perf YTD-17.08%
Dividend Est.- P/FCF- EPS past 5Y17.51% ROI-2529.57% 52W High-89.84% Beta1.44
Dividend TTM- Quick Ratio1.05 Sales past 5Y-20.00% Gross Margin- 52W Low10.43% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.05 EPS Y/Y TTM50.75% Oper. Margin-291.03% RSI (14)45.13 Volatility8.58% 9.13%
Employees35 Debt/Eq- Sales Y/Y TTM- Profit Margin-291.89% Recom1.00 Target Price9.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q58.79% Payout- Rel Volume0.06 Prev Close0.44
Sales Surprise- EPS Surprise-65.62% Sales Q/Q- EarningsMay 09 BMO Avg Volume1.25M Price0.43
SMA20-1.31% SMA50-15.35% SMA200-54.19% Trades Volume18,243 Change-2.72%
Date Action Analyst Rating Change Price Target Change
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
May-21-24 07:00AM
May-09-24 01:55PM
May-07-24 07:30AM
May-02-24 09:00AM
07:00AM Loading…
Apr-30-24 07:00AM
Apr-24-24 07:00AM
Apr-22-24 08:45AM
Apr-19-24 05:10PM
Apr-12-24 08:00AM
Apr-09-24 09:40AM
Mar-27-24 08:07AM
Mar-12-24 02:34PM
Mar-11-24 07:00AM
07:00AM Loading…
Mar-06-24 07:00AM
Feb-29-24 07:00AM
Jan-08-24 06:45AM
Jan-02-24 07:00AM
Dec-12-23 07:00AM
Nov-20-23 07:00AM
Nov-03-23 07:00AM
Oct-27-23 08:00AM
Oct-24-23 08:00AM
Oct-18-23 07:00AM
Oct-13-23 09:30AM
Sep-22-23 07:00AM
Sep-07-23 07:00AM
Aug-11-23 07:00AM
Jul-07-23 10:42AM
11:09AM Loading…
Jul-06-23 11:09AM
Jul-05-23 04:30PM
Jun-23-23 07:00AM
Jun-22-23 07:30AM
Jun-01-23 07:00AM
May-18-23 07:00AM
May-15-23 07:00AM
Apr-28-23 07:00AM
Apr-27-23 09:40AM
Apr-24-23 07:00AM
Apr-05-23 09:40AM
Mar-28-23 07:00AM
Mar-24-23 07:00AM
Mar-22-23 07:00AM
Mar-20-23 09:40AM
Mar-14-23 07:00AM
Mar-13-23 07:54AM
Mar-10-23 07:00AM
Mar-09-23 09:55AM
Mar-08-23 07:00AM
Mar-02-23 09:40AM
Feb-28-23 07:00AM
Feb-24-23 06:00AM
Jan-03-23 07:00AM
Dec-22-22 11:34AM
Dec-19-22 01:53PM
Dec-16-22 07:00AM
Dec-15-22 07:00AM
Nov-21-22 07:00AM
Nov-10-22 02:17PM
Nov-09-22 10:17AM
Nov-08-22 07:00AM
Oct-28-22 07:00AM
Sep-28-22 10:24AM
Sep-14-22 11:05AM
Sep-13-22 07:00AM
Sep-07-22 06:00AM
Sep-02-22 07:00AM
Aug-25-22 07:03AM
Aug-22-22 07:00AM
Aug-12-22 07:00AM
Aug-11-22 07:00AM
Jun-07-22 07:00AM
Jun-06-22 07:00AM
May-31-22 07:00AM
May-20-22 07:00AM
May-18-22 07:00AM
May-10-22 07:00AM
Apr-27-22 07:00AM
Apr-06-22 07:00AM
Apr-01-22 05:00PM
Mar-28-22 07:00AM
Mar-25-22 07:00AM
Mar-18-22 07:00AM
Mar-15-22 07:00AM
Jan-21-22 10:55AM
Jan-20-22 04:05PM
Jan-18-22 08:06AM
Jan-11-22 07:00AM
Jan-06-22 07:00AM
Dec-06-21 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Oct-26-21 07:00AM
Oct-22-21 07:00AM
Oct-18-21 07:00AM
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.